Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion

Blood

Volumn 123, Issue 9, 2014, Pages 1412-1421

  Bachireddy, Pavan ^a,b   Hainz, Ursula ^a   Rooney, Michael ^c   Pozdnyakova, Olga ^b   Aldridge, Julie ^a   Zhang, Wandi ^a   Liao, Xiaoyun ^a   Hodi, F Stephen ^a   O'Connell, Karyn ^a   Haining, W Nicholas ^a   Goldstein, Natalie R ^a   Canning, Christine M ^a   Soiffer, Robert J ^a,b   Ritz, Jerome ^a,b   Hacohen, Nir ^c,d   Alyea III, Edwin P ^a,b   Kim, Haesook T ^a   Wu, Catherine J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; GENE EXPRESSION; GENE STRUCTURE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MICROARRAY ANALYSIS; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANK SUM TEST; TUMOR MICROENVIRONMENT; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; BLOOD DONOR; BONE MARROW CELL; COHORT ANALYSIS; GENETICS; IMMUNOLOGY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; METHODOLOGY; PATHOLOGY; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

TRANSCRIPTOME;

BLOOD DONORS; BONE MARROW CELLS; COHORT STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES, TUMOR-INFILTRATING; T-LYMPHOCYTES; TRANSCRIPTOME; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84897894628     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-08-523001     Document Type: Article

References (47)

1. Kolb HJ, Mittermüller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462-2465.
2. Kolb HJ, Schattenberg A, Goldman JM, et al; European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041-2050.
3. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2):433-444. (Pubitemid 27074209)
4. Soiffer RJ. Donor lymphocyte infusions for acute myeloid leukaemia. Best Pract Res Clin Haematol. 2008;21(3):455-466.
5. Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2011;11(4):473-487.
6. Hardy NM, Fellowes V, Rose JJ, et al. Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood. 2012;119(12):2956-2959.
7. Williams KM, Gress RE. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2008;21(3):579-596.
8. Yun HD, Waller EK. Finding the sweet spot for donor lymphocyte infusions. Biol Blood Marrow Transplant. 2013;19(4):507-508.
9. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36(11):1009-1015. (Pubitemid 41741565)
10. Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654-2666. (Pubitemid 41817714)
11. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964. (Pubitemid 44498003)
12. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942-949. (Pubitemid 39273735)
13. Feuerer M, Beckhove P, Garbi N, et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med. 2003;9(9):1151-1157. (Pubitemid 37173699)
14. Parretta E, Cassese G, Barba P, Santoni A, Guardiola J, Di Rosa F. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J Immunol. 2005;174(12):7654-7664. (Pubitemid 40806270)
15. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 2003;198(11):1753-1757. (Pubitemid 37494167)
16. + T cells preferentially reside in the bone marrow. Blood. 2009;113(10):2238-2244.
17. Lin Y, Zhang L, Cai AX, et al. Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011;121(4):1574-1584.
18. Zhang W, Choi J, Zeng W, et al. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res. 2010;16(10):2729-2739.
19. Champlin R, Jansen J, Ho W, et al. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc. 1991;23(1 Pt 2):1695-1696.
20. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86(11):4337-4343.
21. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91(10):3671-3680. (Pubitemid 28225734)
22. + T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002;8(11):625-632.
23. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15.
24. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
25. Luo B, Cheung HW, Subramanian A, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008;105(51):20380- 20385.
26. + T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670-684.
27. + T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010;16(10):1147-1151.
28. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74(368):829-836.
29. Sairafi D, Remberger M, Uhlin M, Ljungman P, Ringden O, Mattsson J. Leukemia lineagespecific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2010;16(12):1728-1737.
30. Biernacki MA, Marina O, Zhang W, et al. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010;70(3):906-915.
31. Tjin EP, Konijnenberg D, Krebbers G, et al. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res. 2011;17(17):5736-5747.
32. + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949-1955.
33. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492-499.
34. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219-242.
35. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29-37.
36. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25(31):4938-4945. (Pubitemid 350225492)
37. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174(5):2591-2601.
38. + T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 2003;63(10):2561-2568.
39. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612-1621.
40. Yang ZZ, Grote DM, Ziesmer SC, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest. 2012;122(4):1271-1282.
41. + T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350-2360.
42. Bellucci R, Alyea EP, Weller E, et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002;99(12):4610-4617. (Pubitemid 34627234)
43. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
44. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
45. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443- 2454.
46. Riley JL. Combination checkpoint blockade - taking melanoma immunotherapy to the next level. N Engl J Med. 2013;369(2):187-189.
47. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682-687. (Pubitemid 43237609)